Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Venus Continues To Drive TAVR In China By Licensing In Australian Start-Up Tech

Executive Summary

Venus Medtech has agreed a licensing deal with Endoluminal Sciences, an Australian start-up with technology to prevent paravalvular leakage and improve TAVR outcomes.

You may also be interested in...



Minute Insight: Venus Buys Transcatheter Valve Developer Cardiovalve For $300M

Israel-based Cardiovalve is developing a transcatheter valve replacement system to treat mitral and tricuspid valve regurgitation.

China's Venus Persists With Global TAVR Solutions Expansion

Venus Medtech, the Chinese transcatheter aortic valve technology specialist, has made its second international acquisition as it pursues its strategy for global expansion in the TAVR market.

Minute Insight: Agendia Collaborates With Illumina And Brazilian Health Care Providers

The company expects the major commercial collaboration and geographical roll-out will lead to increased adoption of Agendia’s breast cancer diagnostics.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel